ArticleBMC infectious diseases2014
Bridging the data gaps in the epidemiology of hepatitis C virus infection in Malaysia using multi-parameter evidence synthesis.
Article in BMC infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia.The International journal on drug policy · 2017Trial
- Prevalence of Active HCV Infection in Spain in 2022 Using Multiparameter Evidence Synthesis.Journal of viral hepatitis · 2026Article
- Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis.The Lancet regional health. Europe · 2024Article
- Hepatitis C virus (HCV) infection in Malaysia: findings from a nationwide cross-sectional study.The Lancet regional health. Western Pacific · 2023Article
- Assessing feasibility of a modified same-day test-and-treat model for hepatitis C among rural people who inject drugs.Harm reduction journal · 2023Article
- Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options.Frontiers in public health · 2023Article
- The combinatorial diversity of KIR and HLA class I allotypes in Peninsular Malaysia.Immunology · 2021Article
- Hepatitis C Virus Elimination by 2030: Conquering Mount Improbable.Clinical liver disease · 2020Review
- Essential medicines for universal health coverage.Lancet (London, England) · 2017Review
- Estimating the number of people with hepatitis C virus who have ever injected drugs and have yet to be diagnosed: an evidence synthesis approach for Scotland.Addiction (Abingdon, England) · 2015Article
- Projections of the current and future disease burden of hepatitis C virus infection in Malaysia.PloS one · 2015Article
- Hepatitis in Malaysia: Past, Present, and Future.Euroasian journal of hepato-gastroenterologyReview
- Hepatitis Screening and Treatment Campaign in Malaysia-Validation of Low-cost Point of Care Screening Tests and Nucleic Acid Tests for Hepatitis B and C.Euroasian journal of hepato-gastroenterologyArticle
- Chronic Viral Hepatitis in Malaysia: "Where are we now?"Euroasian journal of hepato-gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCollecting adequate information on key epidemiological indicators is a prerequisite to informing a public health response to reduce the impact of hepatitis C virus (HCV) infection in Malaysia. Our goal was to overcome the acute data shortage typical of low/middle income countries using statistical modelling to estimate the national HCV prevalence and the distribution over transmission pathways as of the end of 2009.
methodsMulti-parameter evidence synthesis methods were applied to combine all available relevant data sources - both direct and indirect - that inform the epidemiological parameters of interest.
resultsAn estimated 454,000 (95% credible interval [CrI]: 392,000 to 535,000) HCV antibody-positive individuals were living in Malaysia in 2009; this represents 2.5% (95% CrI: 2.2-3.0%) of the population aged 15-64 years. Among males of Malay ethnicity, for 77% (95% CrI: 69-85%) the route of probable transmission was active or a previous history of injecting drugs. The corresponding proportions were smaller for male Chinese and Indian/other ethnic groups (40% and 71%, respectively). The estimated prevalence in females of all ethnicities was 1% (95% CrI: 0.6 to 1.4%); 92% (95% CrI: 88 to 95%) of infections were attributable to non-drug injecting routes of transmission.
conclusionsThe prevalent number of persons living with HCV infection in Malaysia is estimated to be very high. Low/middle income countries often lack a comprehensive evidence base; however, evidence synthesis methods can assist in filling the data gaps required for the development of effective policy to address the future public health and economic burden due to HCV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.